ALKS
Price
$31.68
Change
-$0.97 (-2.97%)
Updated
Apr 3, 02:28 PM (EDT)
Capitalization
4.55B
20 days until earnings call
ESPR
Price
$1.32
Change
-$0.07 (-5.04%)
Updated
Apr 3, 03:19 PM (EDT)
Capitalization
495.94M
40 days until earnings call
Ad is loading...

ALKS vs ESPR

Header iconALKS vs ESPR Comparison
Open Charts ALKS vs ESPRBanner chart's image
Alkermes
Price$31.68
Change-$0.97 (-2.97%)
Volume$1.4K
Capitalization4.55B
Esperion Therapeutics
Price$1.32
Change-$0.07 (-5.04%)
Volume$200
Capitalization495.94M
ALKS vs ESPR Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. ESPR commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and ESPR is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ALKS: $32.65 vs. ESPR: $1.39)
Brand notoriety: ALKS and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 60% vs. ESPR: 105%
Market capitalization -- ALKS: $4.55B vs. ESPR: $495.94M
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than ESPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 3 TA indicator(s) are bullish while ESPR’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 3 bullish, 5 bearish.
  • ESPR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а -3.09% price change this week, while ESPR (@Pharmaceuticals: Other) price change was -14.72% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.79%. For the same industry, the average monthly price growth was +65.52%, and the average quarterly price growth was -10.15%.

Reported Earning Dates

ALKS is expected to report earnings on Apr 23, 2025.

ESPR is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-2.79% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than ESPR($496M). ALKS YTD gains are higher at: 13.526 vs. ESPR (-36.818). ALKS has higher annual earnings (EBITDA): 519M vs. ESPR (-150.11M). ALKS has more cash in the bank: 773M vs. ESPR (82.2M). ESPR has less debt than ALKS: ESPR (266M) vs ALKS (372M). ALKS has higher revenues than ESPR: ALKS (1.66B) vs ESPR (116M).
ALKSESPRALKS / ESPR
Capitalization4.55B496M918%
EBITDA519M-150.11M-346%
Gain YTD13.526-36.818-37%
P/E Ratio8.90N/A-
Revenue1.66B116M1,434%
Total Cash773M82.2M940%
Total Debt372M266M140%
FUNDAMENTALS RATINGS
ALKS vs ESPR: Fundamental Ratings
ALKS
ESPR
OUTLOOK RATING
1..100
6555
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
20100
SMR RATING
1..100
36100
PRICE GROWTH RATING
1..100
4689
P/E GROWTH RATING
1..100
10100
SEASONALITY SCORE
1..100
2350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for ALKS (100). This means that ESPR’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (20) in the Biotechnology industry is significantly better than the same rating for ESPR (100). This means that ALKS’s stock grew significantly faster than ESPR’s over the last 12 months.

ALKS's SMR Rating (36) in the Biotechnology industry is somewhat better than the same rating for ESPR (100). This means that ALKS’s stock grew somewhat faster than ESPR’s over the last 12 months.

ALKS's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for ESPR (89). This means that ALKS’s stock grew somewhat faster than ESPR’s over the last 12 months.

ALKS's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for ESPR (100). This means that ALKS’s stock grew significantly faster than ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSESPR
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 11 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCBAX13.74N/A
N/A
BlackRock Large Cap Focus Value Inv C
MSFHX19.30N/A
N/A
MFS Total Return R3
WRLDX36.78N/A
N/A
Scharf Global Opportunity Institutional
JIHIX17.33N/A
N/A
JPMorgan International Hedged Equity I
NWAMX34.05N/A
N/A
Nationwide BNY Mellon Dyn US Eq Inc K

ALKS and

Correlation & Price change

A.I.dvisor tells us that ALKS and ACET have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+0.37%
ACET - ALKS
30%
Poorly correlated
-1.50%
ESPR - ALKS
28%
Poorly correlated
-1.42%
ZTS - ALKS
25%
Poorly correlated
+0.98%
DVAX - ALKS
25%
Poorly correlated
+1.26%
VTRS - ALKS
24%
Poorly correlated
+0.70%
More